salvage pathway comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide composed of two nucleotides joined by phosphate groups. One nucleotide contains adenine; the other contains nicotinamide. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, and the reversible hydride transfer between them underlies many metabolic oxidation-reduction reactions. In cells, NAD+ serves as an electron acceptor in pathways such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Its concentration and redox ratio vary by compartment, tissue, and metabolic state.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
In redox reactions, NAD+ accepts a hydride ion, which consists of two electrons and one proton. The hydride adds to the nicotinamide ring at a specific carbon, converting NAD+ into NADH. Dehydrogenase enzymes use this step in glycolysis, the citric acid cycle, and fatty acid oxidation. NADH later donates electrons to the mitochondrial electron transport chain, helping to drive ATP synthesis. The balance between NAD+ and NADH reflects the metabolic state of a cell, and shifts in that balance can alter how pathways operate.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave it and attach its ADP-ribose portion to other molecules. This group includes poly(ADP-ribose) polymerases, CD38, and sirtuins. Such reactions consume NAD+ and can influence its availability for metabolism. Cells replenish NAD+ through a salvage pathway that recycles nicotinamide and through routes starting from tryptophan or vitamin B3 forms. How these synthesis and consumption routes are coordinated across tissues remains an active area of study, and compartment-specific concentrations are difficult to measure directly.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide built from adenine, nicotinamide, two ribose sugars, and two phosphate groups. The oxidized form carries a positive charge on the nicotinamide ring, while the reduced form, NADH, is neutral. This pair acts as a reversible electron carrier in cells. NAD+ is present in bacteria, plants, animals, and fungi. Its structure allows it to accept and donate electrons without being consumed in the reactions it supports.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C21H27N7O14P2 | Free acid form; salt and hydrate forms differ in mass. |
| Molar mass | 663.43 g/mol | Anhydrous free acid; counterions and water change the value. |
| Appearance | White to off-white powder | Typical solid reagent; exact color varies by purity and form. |
| Solubility class | Highly water-soluble | Aqueous solutions are acidic; organic solubility is generally limited. |
| Common synonyms | DPN, coenzyme I, NAD | Older literature often uses diphosphopyridine nucleotide or DPN. |
NAD+ is commonly measured by high-performance liquid chromatography with ultraviolet detection, often at 254 or 260 nm. Enzymatic cycling assays provide higher sensitivity by coupling NAD+ to a reporter reaction. Mass spectrometry can distinguish NAD+ from close analogues and confirm isotope labeling. Sample preparation usually involves rapid quenching of metabolism to prevent interconversion with NADH. Because NAD+ and NADH differ by one hydride, extraction conditions strongly affect the measured ratio.
In aqueous solution, NAD+ is most stable under mildly acidic to neutral conditions and degrades faster at high pH or elevated temperature. The molecule can hydrolyze at the pyrophosphate bond or undergo nonenzymatic cyclization. Buffers, chelating agents, and cold temperatures slow these losses during analysis. Repeated freeze-thaw cycles are generally avoided because they can promote degradation and concentration changes. Light exposure is also controlled, though NAD+ is less photolabile than some related nucleotides.
Commercial NAD+ is supplied as a solid, often as the free acid or a salt, and purity is verified by chromatographic methods. Laboratories typically store it desiccated at minus 20 degrees Celsius or below. Working solutions are prepared fresh because even sterile aqueous solutions can lose activity over hours to days depending on pH and temperature. Documentation may include a certificate of analysis, an assay value, and a recommended retest date. Researchers should verify identity and purity when results depend on precise cofactor concentrations.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
Stability studies show that NAD+ can hydrolyze under prolonged heat, extreme pH, or microbial contamination. Phosphate buffers near neutral pH are often used for short-term handling, though exact stability depends on concentration, temperature, and matrix. In biological samples, endogenous enzymes can rapidly degrade NAD+, making cold chain and fast processing important. Analytical reports should state extraction conditions, internal standards, and validation parameters. Without those details, comparisons across studies remain difficult and potentially misleading.
Laboratory measurement of NAD+ often begins with rapid quenching of cell or tissue samples to prevent enzymatic conversion. Acidic or alkaline extraction can precipitate proteins, but the chosen method affects recovery of oxidized and reduced forms. Enzymatic cycling assays provide high sensitivity by amplifying a NAD+-dependent reaction. High-performance liquid chromatography and mass spectrometry offer separation and structural confirmation. Each method has trade-offs in throughput, specificity, and the ability to distinguish NAD+ from close analogues.
Trapoxin, (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8- oxo-9,10-epoxy-decanoyl)), is commonly known as an anti-tumor cyclic tetra-peptide. In a prior study, it has been found that the fungal product, Trapoxin, can induce morphological reversion from transformed to normal in sis-transformed NIH3T3 fibroblasts. It was also found that trapoxin can cause highly acetylated core histones in many different mammalian cell lines to accumulate. Vitro experiments were conducted, and it was found that a low concentration of trapoxin could irreversibly inhibit deacetylation of acetylated histone molecules. The study reported that this could be due to the chemical reduction of an epoxide group, that is in trapoxin, completely abolishing the inhibitory activity. This suggested that trapoxin binds covalently to the histone deacetylase via the epoxide. On the contrary, the inhibition by trichostatin A, which is a known potent inhibitor of histone deacetylase, could be reversible. Despite their mode of inhibitions being different, trapoxin and trichostatin A had nearly the same biological effects on the cell cycle. The in vivo effects that are commonly induced by these agents could be attributed to histone hyperacetylation that results from the inhibition of histone deacetylase, which was strongly suggested from the results.
=== Addiction and withdrawal === Aticaprant was well-tolerated in cocaine use disorder (CUD) patients. A positron emission tomography (PET) study in CUD patients utilizing a KOR selective agonist [11C]GR-103545 radioligand showed CUD individuals with higher KOR availability were more prone to stress-induced relapse. A subsequent PET scan following a three-day cocaine binge showed a decrease in KOR availability, interpreted as increased endogenous dynorphin competing with the radioligand at the KOR binding sites. These findings are in support of the negative affect state and further implicate the KOR/dynorphin system clinically and therapeutically relevant in humans with CUD. Taken together, in drug addiction the KOR system is implicated as a homeostatic mechanism to counteract the acute effects of drugs of abuse. Chronic drug use and stress up-regulate the system in turn leading to a dysregulated state which induces negative affective states and stress reactivity. KOR agonists have also been investigated for their therapeutic potential in the treatment of addiction, particularly substance use disorders. Ibogaine, atypical KOR agonist with G-protein-biased signaling and complex pharmacodynamics involving multiple neurotransmitter systems. Ibogaine's primary active metabolite, noribogaine, acts as a moderate KOR agonist selective for G protein and a potent serotonin reuptake inhibitor. This mechanism, combined with activity at 5-HT2A, 5-HT2C, σ2, and NMDA receptors, likely leads its anti-addictive effects.
Smallpox was eradicated by a massive international search for outbreaks, backed up with a vaccination program, starting in 1967. It was organised and co-ordinated by a World Health Organization (WHO) unit, set up and headed by Donald Henderson. The last case in the Americas occurred in 1971 (Brazil), south-east Asia (Indonesia) in 1972, and on the Indian subcontinent in 1975 (Bangladesh). After two years of intensive searches, what proved to be the last endemic case anywhere in the world occurred in Somalia, in October 1977. A Global Commission for the Certification of Smallpox Eradication chaired by Frank Fenner examined the evidence from, and visited where necessary, all countries where smallpox had been endemic. In December 1979 they concluded that smallpox had been eradicated; a conclusion endorsed by the WHO General Assembly in May 1980. However, even as the disease was being eradicated there still remained stocks of smallpox virus in many laboratories. Accelerated by two cases of smallpox in 1978, one fatal (Janet Parker), caused by an accidental and unexplained containment breach at a laboratory at the University of Birmingham Medical School, the WHO ensured that known stocks of smallpox virus were either destroyed or moved to safer laboratories. By 1979, only four laboratories were known to have smallpox virus.
2 FeCl3 + 2 H2O + SO2 → 2 FeCl2 + H2SO4 + 2 HCl 2 CuCl2 + 2 H2O + SO2 → 2 CuCl + H2SO4 + 2 HCl Two less well-known laboratory methods of producing sulfuric acid, albeit in dilute form and requiring some extra effort in purification, rely on electrolysis. A solution of copper(II) sulfate can be electrolyzed with a copper cathode and platinum/graphite anode to give spongy copper at cathode and oxygen gas at the anode. The solution of dilute sulfuric acid indicates completion of the reaction when it turns from blue to clear (production of hydrogen at cathode is another sign):
Sources: en.wikipedia.org
mismatch Also mispairing. An incorrect pairing of nucleobases on complementary strands of DNA or RNA; i.e. the presence in one strand of a duplex molecule of a base that is not complementary (by Watson–Crick pairing rules) to the base occupying the corresponding position in the other strand, which prevents normal hydrogen bonding between the bases. For example, a guanine paired with a thymine would be a mismatch, as guanine normally pairs with cytosine.
The birth rate (9.49‰, 2012) is much lower than the mortality rate (11.84‰, 2012), resulting in a shrinking (−0.26% per year, 2012) and aging population (median age: 41.6 years, 2018), one of the oldest populations in the world, with approximately 16.8% of total population aged 65 years and over. The life expectancy in 2015 was estimated at 74.92 years (71.46 years male, 78.59 years female). The number of Romanians and individuals with ancestors born in Romania living abroad is estimated at 12 million. After the Romanian Revolution of 1989, a significant number of Romanians emigrated to other European countries, North America or Australia. For example, in 1990, 96,919 Romanians permanently settled abroad.
=== Reducing huntingtin production === Gene silencing aims to reduce the production of the mutant protein, since HD is caused by a single dominant gene encoding a toxic protein. Gene silencing experiments in mouse models have shown that when the expression of mHtt is reduced, symptoms improve. The safety of RNA interference and allele-specific oligonucleotide (ASO) methods of gene silencing have been demonstrated in mice and macaques. Allele-specific silencing approaches attempt to target mHTT while leaving wild-type HTT untouched by leveraging polymorphisms present on only the mutant allele. The first gene silencing trial in humans with HD began in 2015, testing the safety of IONIS-HTTRx, produced by Ionis Pharmaceuticals and led by UCL Institute of Neurology. Mutant huntingtin was detected and quantified for the first time in cerebrospinal fluid from HD mutation-carriers in 2015 using a novel "single-molecule counting" immunoassay, providing a direct way to assess whether huntingtin-lowering treatments are achieving the desired effect. A phase 3 trial of this compound, renamed tominersen and sponsored by Roche Pharmaceuticals, began in 2019 but was halted in 2021 after the safety monitoring board concluded that the risk-benefit balance was unfavourable. A huntingtin-lowering gene therapy trial run by Dutch pharmaceutical company uniQure Biopharma began in 2019, and several trials of orally administered huntingtin-lowering splicing modulator compounds have been announced; of these, votoplam is through Phase 2 trial in 2025.
Sources: en.wikipedia.org
The three substrates of this enzyme are trans-zeatin, reduced nicotinamide adenine dinucleotide phosphate (NADPH) and a proton. Its products are dihydrozeatin and NADP+. The enzyme does not act on cis-zeatin. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is dihydrozeatin:NADP+ oxidoreductase.
=== Germanium batteries === The company was developing germanium-based batteries by 2017, citing graphite-free batteries and an electric vehicle battery that fully charges in five minutes, expecting "millions of cars" to be equipped with its electric vehicle battery by 2020. The company announced in 2018 that its mobile phone battery would be commercially available by 2019, and that it had plans to build a battery factory in the United States by 2022. In 2019 it announced the commercialization of a 168-cell germanium-tin battery for electric scooters, and stated that its mobile phone products would be commercially available in late 2020 and the scooter battery would be commercially available in 2021. The company's CEO said its electric car battery would have ten times as many cells as the scooter battery, charge fast enough to add 300 miles of range in under five minutes, and have a cooling system; and that its batteries did not degrade. A 2019 peer-reviewed study concluded that the company's stated battery capabilities have no basis in published, peer-reviewed literature, and listed its unreleased products. Science journalist John Timmer could not identify in 2021 any published research about the company's germanium battery technology.
Siddhartha Roy (born 1 April 1954) is an Indian Chemical and Structural biologist, biophysicist, former director of the Indian Institute of Chemical Biology and the former director (officiating) of Bose Institute. Widely known for his studies on Gene Regulation, Peptidomimetics, bacteriophage lambda and protein synthesis, he is an elected fellow of the Indian Academy of Sciences and the Indian National Science Academy. In 1999, the Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, for his contributions to Biological sciences.
=== Maluku province === Alune people Ambonese people Haruku people Hitu people Saparua people Aru people Ujir people Babar people Banda people Bati people Buano people Buru people Ambelau people Kayeli people Lisela people Masarete people Rana people Wai Apu people Wai Loa people Geser people Gorom people Kei people Tanimbar Kei people Kisar people Leti people Manipa people Masela people Mausu Ane people Meher people Nuaulu people Oirata people Tanimbarese people Teon–Nila–Serua (TNS) Nila people Serua people Teon people Teor people Von people Wemale people Wetar people Yamatitam people
Sources: en.wikipedia.org
NAD+ is a coenzyme found in all living cells. It carries electrons in metabolic reactions and also serves as a substrate for enzymes involved in signaling and DNA repair. Its oxidized and reduced forms are central to energy metabolism.
NAD+ is the oxidized form and NADH is the reduced form. The pair accepts and donates electrons in redox reactions. Their ratio helps indicate the metabolic state of a cell or compartment.
No. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors that cells can convert into NAD+. They are distinct molecules with different absorption and metabolism profiles.
It indicates the oxidized form, which has a positive charge on the nicotinamide nitrogen. The reduced partner NADH lacks that charge and carries added electrons. The plus sign is part of the standard abbreviation, not a separate ion.